Novacyt Stock

Novacyt Intangible Assets

The Intangible Assets of Novacyt (ALNOV.PA) as of Sep 4, 2026 is 17.58 M GBP. In the previous year, Intangible Assets was 10.23 M GBP — a change of 71.77% (higher).

Intangible Assets

17.58 MGBP

YoY

71.77%

Last updated:

Intangible Assets of Novacyt is 2026 17.58 M GBP. Intangible Assets of Novacyt was 2025 10.23 M GBP. It decreases by 71.77% higher compared to the previous year.

The Novacyt Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
4.20 M GBP
Jan 1, 2018
4.46 M GBP
Jan 1, 2019
3.68 M GBP
Jan 1, 2020
4.26 M GBP
Jan 1, 2021
3.71 M GBP
Jan 1, 2022
3.12 M GBP
Jan 1, 2023
10.23 M GBP
Jan 1, 2024
17.58 M GBP
The Novacyt Intangible Assets history
YEARIntangible AssetsYoY
17.58 MGBP+71.77%
10.23 MGBP+227.84%
3.12 MGBP-15.88%
3.71 MGBP-12.81%
4.26 MGBP+15.53%
3.68 MGBP-17.38%
4.46 MGBP+6.14%
4.20 MGBP-8.40%
4.59 MGBP+253.56%
1.30 MGBP+18.23%
1.10 MGBP
Access this data via the Eulerpool API

Novacyt Stock analysis

What does Novacyt do? Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novacyt stock

Intangible Assets of Novacyt is 17.58 M GBP in 2026.

Intangible Assets of Novacyt changed from 10.23 M GBP to 17.58 M GBP, representing a 71.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Novacyt since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Novacyt historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Novacyt

All Key Metrics — Novacyt